Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MapLight TherapeuticsMPLT +3.78%14 3-1 Month Momentum % is 2.99% as of Jul. 26, 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,395 Biotechnology companies, MapLight Therapeutics ranks better than 70.82% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-26), MapLight Therapeutics's 3-1 Month Momentum % is 2.99%.
The industry rank for MapLight Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
MPLT's 3-1 Month Momentum % is ranked better than 70.82% of 1395
companies
in the Biotechnology industry
Industry Median: -10.71
vs MPLT: 2.99
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
MapLight Therapeutics 3-1 Month Momentum % Related Terms
MPLT vs COAG, CAPR, NVAX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, MapLight Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MapLight Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where MapLight Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MapLight Therapeutics (MPLT) has a 3-1 Month Momentum % of 2.99% as of Jul. 26, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on MapLight Therapeutics and its competitors. According to the industry distribution chart, MapLight Therapeutics ranks #407 out of 1395 companies in the Biotechnology industry, placing it in the top 29.2%.
Is MapLight Therapeutics' 3-1 Month Momentum % too high?
MapLight Therapeutics' current 3-1 Month Momentum % is 2.99%. Based on the distribution chart, MapLight Therapeutics ranks #407 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' 3-1 Month Momentum % compare to COAG and CAPR?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #407 out of 1395 companies for 3-1 Month Momentum %. This puts MapLight Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current 3-1 Month Momentum % is 2.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current 3-1 Month Momentum % of 2.99%. The current 3-1 Month Momentum % is 2.99%. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current 3-1 Month Momentum % is 2.99% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score
Get the complete analysis for MPLT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPLT has been successfully added to your 
